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Malaria in Pregnancy
TL MAGWALI
Introduction
It is estim ated that nearly  five b illion  episodes o f  clinical m alaria  occur w orldw ide each year. The disease 
causes about three m illion  deaths annually  w ith  A frica suffering 90%  o f  this bu rden .'it is also estim ated that 
25 m illion w om en fall p regnant in  the m alaria-endem ic areas o f  A frica each year.2 M ost o f  the deaths due to 
m alaria in A frica are in  pregnan t w om en and children under the age o f  five years.3
Plasmodium falciparum  causes the m ost severe m alarial illness and m ost cases in  A frica are caused by this 
species o f  the m alaria  parasite.3T he prevalence o f  Plasmodium falciparum  infection am ong pregnant w om en 
in  rural areas in parts o f  A frica can  be very  high. V erhoff and co-w orkers found a  prevalence o fplasmodium 
falciparum  m alaria  o f  35.3%  am ong primigravidae and 13.6%  in multigravidae in a study done am ong 
pregnant w om en in rural M alaw i.4
W om en w ho live in areas o f  h igh  o r m oderate (stable) m alaria transm ission have a  degree o f  im m unity to 
m alaria w hereas w om en w ho live in  areas o f  low  (unstable) m alaria  transm ission usually  have no im m unity to 
the disease.5
Pregnancy is know n to  cause a  low ered capacity  for type 1 im m une response.6 This reduces im m unity to 
diseases such as m alaria, tuberculosis and leishm aniasis.
Effect of Pregnancy on Malaria.
Women who live in malaria endemic areas may have an 
asym ptom atic background parasitaem ia. This 
asymptomatic parasitaemia can be punctuated by 
episodes o f acute febrile illness due to malaria. The 
incidence o f these episodes o f febrile illness due to 
malaria increases during pregnancy especially in 
primigravidae and the duration of illness may be 
significantly longer.7
Pregnant women, especially those living in areas of 
low or unstable transmission, are more likely to suffer 
from the severe complications o f Malaria compared to 
non-pregnant individuals living in the same area. These 
complications include cerebral malaria, 
hypoglycaemia, pulmonary oedema and severe 
haemolytic anaemia.8,9
Effect of Malaria on Pregnancy.
Malaria parasites have a high affinity for the decidual 
cells o f the placenta. The intervillous spaces may be 
heavily parasitized with a heavy presence o f
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macrophages.10 In a study done among 1 177 rural 
women in Tanzania, evidence o f  malaria infection was 
found in 75.5% of placental samples." The incidence of 
the malarial parasite actually crossing the placenta 
(congenital malaria) is low, however, and is quoted at 
around 3%.12 Heavy parasitization o f the placenta may 
lead to impaired nutrient and oxygen transfer to the 
growing foetus. This leads to an increased risk of 
miscarriage and premature labour in women who have 
suffered malaria during pregnancy.13,14
Another possible consequence of placental malaria 
is intra-uterine growth restriction and subsequent low 
birth weight. Malaria in pregnancy is estimated to 
contribute eight to 14% low birth weight babies in 
endemic areas.2 Women who have suffered malaria 
during pregnancy have a higher stillbirth rate.13
A complication o f the acute or chronic haemolysis k 
that occurs in malaria is anaemia. Malaria contributes 
three to 15% o f  severe anaemia cases in pregnant 
women in endemic areas.2
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M alaria in Pregnancy and H IV  Infection.
Immunity to malaria can be further reduced in women 
who are HIV positive. The prevalence and severity of 
malaria in pregnancy have been shown to be higher in 
HIV positive women. The parasite density, prevalence 
of anaemia and incidence o f cerebral malaria are all 
higher in HIV positive compared to HIV negative 
women. The efficacy o f sulfadoxine/pyrimethamine 
(SP) in reducing placental parasitaemia has been 
shown to be impaired.15,16
Diagnosis.
It is worth noting that the clinical features o f malaria 
may be atypical in pregnancy, for example the fever 
may not follow the usual remittent pattern. In some 
cases maternal anaemia may be the only presenting 
feature especially in multigravidae.3
Treatm ent of M alaria  D uring Pregnancy.
Plasmodium falciparum has shown resistance to 
chloroquine in most areas o f Africa.17'18 Use o f a 
combination o f Arthemeter and Lumefantrine for the 
treatment o f malaria was shown to be more cost- 
e f f e c t i v e  t h a n  u s in g  c h l o r o q u i n e  a n d  
Sulfadoxine/pyrimethamine (SP). Widespread use o f 
the Arthemeter/Lumefantrine combination may be 
limited by lack o f resources in most parts o f Africa.18
Malaria in pregnancy can be treated with oral 
quinine 600mg six hourly for seven days followed by 
clindamycin 300mg. orally six hourly for five days. 
Doxycycline cannot be used as the follow-up treatment 
to Quinine as use o f the former is contra-indicated 
during pregnancy. In very ill patients Quinine 20mg/kg 
can be given as a loading dose followed, by lOmg/kg 
over four hours given eight hourly. The loading and 
maintenance doses are all given as infusion. The 
maintenance dose is continued until the patient can take 
orally.19
Artemisinin derivatives may be used in pregnancy 
when benefits outweigh the risks. Their use is not 
recommended in the first trimester. WHO advocates 
the use o f artemisinin derivatives in combination with 
other drugs (artemisinin based combination therapies 
ACT's). Coartem is a combination o f arthemeter and 
lumefantrine. It is given in a dose o f four tablets twice 
daily for three days.19
Benign Form s of M alaria
Plasmodium vivax, ovale and malariae are still largely 
sensitive and will respond to a standard dose 
chloroquine. The hypnozoites (dormant liver forms) of 
Plasmodium vivax and Plasmodium ovale are treated 
with primaquine. Primaquine is contra-indicated 
during pregnancy as it may possibly cause haemolysis 
in the foetus. In cases o f Plasmodium vivax or ovale 
infection during pregnancy, the patient should be given 
chloroquine 600mg weekly until delivery after she has 
completed the standard dose o f treatment. Primaquine 
is then given after delivery in a dose o f 30mg once daily 
for 30 days in case o f vivax infection and 15mg daily for
30 days in the case o f  malariae infection.19 
Prophylaxis.
Pregnant women travelling from non-endemic to 
endemic areas need prophylaxis against malaria. Such 
travel should be discouraged unless it is absolutely 
necessary. If  at all possible, such travel should ideally 
be undertaken after the first trimester. As prophylaxis, a 
combination o f pyrimethamine and dapsone should be 
given once a week starting two weeks before entering 
the malarious area, continuing whilst in the area and 
continuing for four weeks after leaving the area. Folic 
acid supplementation should be given when this 
prophylaxis is given.19
Intermittent Preventive Treatment.
WHO recommends Intermittent Preventive Treatment 
(IPT) as one o f the strategies against malaria in 
pregnancy in women who live in endemic areas. The 
other two are use o f  insecticide treated nets (ITN's) and 
effective case management. IPT involves the giving o f 
a total o f three doses o f SP at intervals o f at least one 
month apart. The IPT is started soon after the first 
trimester and after when the first movements are felt. 
Supplementation with ferrous sulphate and folate 
should also be given to all pregnant women who live in 
endemic areas. For endemic areas, WHO also 
recommends spraying programmes and continuing 
medical education to health professionals who work in 
malaria endemic areas.5
IPT has been shown to reduce the prevalence of 
anaemia in women living in endemic areas and to 
reduce the incidence o f low birth weight.4 The benefits 
o f IPT with SP may soon be undermined by increasing 
levels o f resistance to SP. Research on several 
candidate alternative combinations is on-going.20
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